Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-03-01 Option Award | 2024-11-27 6:04 pm | N/A 2034-02-28 | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 315,316 | $0 | 315,316 (Direct) | View |
2024-11-21 Tax Withholding | 2024-11-25 4:29 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 19,910 | $6.44 | 2,659,593 (Direct) | View |
2024-11-14 Tax Withholding | 2024-11-18 4:26 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 60,256 | $7.92 | 2,679,503 (Direct) | View |
2024-08-21 Tax Withholding | 2024-08-23 4:11 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 79,616 | $9.19 | 2,739,759 (Direct) | View |
2024-08-14 Tax Withholding | 2024-08-16 4:47 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 59,765 | $7.02 | 2,819,375 (Direct) | View |
2024-05-14 Tax Withholding | 2024-05-16 6:54 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 54,918 | $8.36 | 2,879,630 (Direct) | View |
2024-02-14 Tax Withholding | 2024-02-16 5:06 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 41,861 | $3.4 | 2,935,038 (Direct) | View |
2023-11-14 Tax Withholding | 2023-11-16 7:41 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 239,023 | $5.08 | 2,977,478 (Direct) | View |
2023-08-21 Option Award | 2023-08-23 4:19 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 493,994 | $0 | 3,218,401 (Direct) | View |
2023-05-31 Exercise | 2023-06-01 8:40 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 33,605 | $3.88 | 2,877,492 (Direct) | View |
2023-05-31 Exercise | 2023-06-01 8:40 pm | N/A 2032-03-22 | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 33,605 | $0 | 2,877,492 (Direct) | View |
2022-11-14 Option Award | 2022-11-16 7:05 pm | N/A 2032-11-13 | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 1,785,336 | $0 | 2,951,191 (Direct) | View |
Ownership | 2022-11-09 8:30 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter President and CEO | 0 | $0 | 1,601,465 (Direct) | View |